CelLBxHealth (CLBX) Stock Overview
A medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
CLBX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CelLBxHealth plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.018 |
| 52 Week High | UK£0.083 |
| 52 Week Low | UK£0.0085 |
| Beta | 0.41 |
| 1 Month Change | 65.12% |
| 3 Month Change | 86.84% |
| 1 Year Change | -77.81% |
| 3 Year Change | -87.76% |
| 5 Year Change | -98.57% |
| Change since IPO | -98.81% |
Recent News & Updates
Narrative Update • Jun 05
CLBX: Lung Cancer Study Will Support Future Upside Narrative
Analysts have maintained their fair value estimate for CelLBxHealth at £0.04 per share. A slightly lower discount rate and marginal adjustments to assumptions for revenue growth, profit margin and future P/E have resulted in an unchanged price target.Narrative Update • May 22
CLBX: Lung Cancer Study And New Sales Leadership Will Drive Upside
Analysts have slightly revised their price target for CelLBxHealth, keeping fair value at £0.04 while fine tuning assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News CelLBxHealth issued revenue guidance for fiscal 2026, indicating an expectation of at least £2.1 million, described as a 50% increase on fiscal 2025, alongside ongoing cost reduction efforts (Corporate Guidance).Narrative Update • May 04
CLBX: Lung Cancer Collaboration And Cost Discipline Will Support Future Upside
Analysts have reduced their price target for CelLBxHealth from £0.07 to £0.04. This reflects updated assumptions around discount rates, profit margins, and a lower future P/E multiple.Recent updates
Narrative Update • Jun 05
CLBX: Lung Cancer Study Will Support Future Upside Narrative
Analysts have maintained their fair value estimate for CelLBxHealth at £0.04 per share. A slightly lower discount rate and marginal adjustments to assumptions for revenue growth, profit margin and future P/E have resulted in an unchanged price target.Narrative Update • May 22
CLBX: Lung Cancer Study And New Sales Leadership Will Drive Upside
Analysts have slightly revised their price target for CelLBxHealth, keeping fair value at £0.04 while fine tuning assumptions around the discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News CelLBxHealth issued revenue guidance for fiscal 2026, indicating an expectation of at least £2.1 million, described as a 50% increase on fiscal 2025, alongside ongoing cost reduction efforts (Corporate Guidance).Narrative Update • May 04
CLBX: Lung Cancer Collaboration And Cost Discipline Will Support Future Upside
Analysts have reduced their price target for CelLBxHealth from £0.07 to £0.04. This reflects updated assumptions around discount rates, profit margins, and a lower future P/E multiple.
Narrative Update • Apr 19
CLBX: Regulatory Streamlining And Refocused Resources Will Support Future Upside Potential
Analysts have adjusted their price target on CelLBxHealth, highlighting higher assumed revenue growth, a wider profit margin and a lower future P/E multiple as key inputs to their revised fair value view. What's in the News CelLBxHealth decided to discontinue maintenance of its FDA establishment license and device listing for the Parsortix system, aligning its regulatory approach with current operational and commercial priorities (Key Developments).Narrative Update • Apr 04
CLBX: Cost Discipline And Refocused Regulatory Approach Will Support Future Oncology Upside
Analysts have kept their fair value estimate for CelLBxHealth steady at £0.07 per share, with a slightly higher discount rate and a small adjustment to long term profit margin and future P/E assumptions guiding this latest price target update. What's in the News CelLBxHealth decided to discontinue maintenance of its FDA establishment license and device listing for the Parsortix system, aligning its regulatory approach with current operational and commercial priorities while focusing on cost discipline (Key Developments).Narrative Update • Mar 20
CLBX: Cost Discipline And Regulatory Streamlining Will Support Future Oncology Upside
CellBxHealth’s analyst price target has been reset to £0.07. Analysts attribute this to consistent fair value assumptions, a slightly lower discount rate, a marginally higher profit margin outlook, and a modestly reduced future P/E multiple.Narrative Update • Mar 06
CLBX: Cost Discipline And Refocused Resources Will Support Oncology Upside
Analysts have modestly raised their price target on CelLBxHealth, citing an unchanged intrinsic value estimate of about £0.07 per share, slightly higher assumed discount rates, a marginally higher future P/E expectation, and a small reduction in projected profit margins. What's in the News CelLBxHealth plc decided to discontinue maintenance of its FDA establishment license and device listing for the Parsortix system, aligning regulatory obligations with current operational and commercial priorities (Key Developments).Narrative Update • Feb 19
CLBX: Equity Raises And Lower Risk Profile Will Support Oncology Upside
Analysts have raised their target price for CelLBxHealth to £0.07. The updated view reflects revised assumptions around the discount rate, profit margin, revenue growth, and future P/E multiples.
Narrative Update • Feb 05
CLBX: Future Repricing Will Rely On Equity Raises And Margin Expansion
Analysts have raised their price target for CelLBxHealth, citing slightly lower assumed discount rates, a modest uptick in projected revenue growth and profit margins, and a reduced future P/E of about 45x as the main factors behind the change. What's in the News CelLBxHealth completed a follow-on equity offering of £7.208915 million, issuing multiple blocks of ordinary shares at £0.01 per share.Narrative Update • Jan 22
CLBX: Equity Raises And QIAGEN Alliance Will Support Future Upside Potential
Analysts have trimmed their fair value estimate for CelLBxHealth from US$0.17 to US$0.04. This reflects updated assumptions around revenue growth, profit margins, discount rate and future P/E expectations.Narrative Update • Jan 08
CLBX: Future Profitability Assumptions Will Drive Bullish Repricing Potential
Analysts have reduced their price targets on CelLBxHealth, citing updates to fair value assumptions, a higher discount rate, more moderate revenue growth expectations, improved profit margin estimates toward 9.49%, and a revised future P/E of about 53.37x. What's in the News CelLBxHealth plc has filed follow on equity offerings totaling £8.67 million across multiple tranches of ordinary shares at £0.01, including securities with a subsequent direct listing feature.Narrative Update • Dec 23
CLBX: Equity Raises Will Drive Future Oncology Partnerships And Upside Potential
Analysts have nudged their price target on CelLBxHealth slightly higher to reflect updated valuation models, with modest adjustments to the discount rate, long term profit margin expectations, and forward earnings multiples. These revisions now support an intrinsic value estimate of approximately $0.07 per share.Narrative Update • Dec 09
CLBX: Equity Raises Will Fund Future Oncology Partnerships And Upside Potential
Analysts have lowered their price target on CelLBxHealth from approximately $0.11 to $0.07 per share, citing a higher required discount rate, more conservative long term revenue growth assumptions, and a higher future P/E multiple that together point to a more tempered outlook for upside. What's in the News CelLBxHealth completed a £7.21 million follow on equity offering, issuing over 720 million ordinary shares at £0.01 per share, alongside a subsequent direct listing (company filing).Narrative Update • Nov 25
CLBX: New Partnerships And Equity Raise Will Drive 2025 Performance
Narrative Update on CelLBxHealth Analysts have maintained CelLBxHealth's target price at $0.11 per share, citing improved profit margin estimates and a slightly higher discount rate in their updated valuation model. What's in the News Entered a non-exclusive collaboration and co-marketing agreement with QIAGEN Manchester Ltd., allowing the Parsortix platform to be offered in pharmaceutical projects that combine CTC enrichment and molecular analysis tools (Key Developments) Completed a follow-on equity offering totaling £6.8 million through the issuance of common stock (Key Developments) Filed additional follow-on equity offerings amounting to £1 million and £8.67 million to raise further capital (Key Developments) Special/Extraordinary Shareholders Meeting scheduled for December 15, 2025, in London (Key Developments) Changed company name from ANGLE plc to CelLBxHealth plc effective October 29, 2025 (Key Developments) Valuation Changes Fair Value estimate remains stable at $0.105 per share, showing no change from previous assessments.Narrative Update • Nov 10
CLBX: Revenue Shifts And Leadership Changes Will Shape 2025 Outlook
Analysts have revised their price target for CelLBxHealth, maintaining the fair value at $0.105. Adjustments in the discount rate reflect a reassessment of market conditions and risk profiles.Narrative Update • Oct 27
Leadership Appointment And Diagnostic Partnerships Will Shape Future Market Expansion
Analysts have maintained ANGLE's fair value estimate at $0.11 per share. Their outlook remains steady after a review of updated company fundamentals and underlying discount rates.Narrative Update • Oct 13
Pharma Partnerships And Liquid Biopsy Will Expand Future Markets
Analysts have lowered their price target for ANGLE from $0.17 to $0.105. They cite updated projections of higher revenue growth, but reduced profit margins and a higher discount rate are impacting the company's fair value assessment.Narrative Update • Sep 11
Pharma Partnerships And Liquid Biopsy Will Expand Future Markets
Despite a substantial increase in consensus revenue growth forecasts, ANGLE’s future P/E multiple has halved, reflecting a notable de-rating and driving the fair value estimate down from £0.28 to £0.17. What's in the News ANGLE plc announced a collaboration with Myriad Genetics, utilising ANGLE's Parsortix system to process cancer patient blood samples for molecular analysis, comparing CTC-DNA with matched tissue samples via Myriad's assay; further details remain confidential.New Narrative • Jun 01
Pharma Partnerships And Liquid Biopsy Will Expand Future Markets
ANGLE's unique technologies and partnerships in precision oncology position it for strong, margin-expanding revenue growth as liquid biopsy adoption accelerates.Analysis Article • May 30
Is ANGLE (LON:AGL) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analysis Article • Jan 22
Here's Why We're Watching ANGLE's (LON:AGL) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Sep 27
Will ANGLE (LON:AGL) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analysis Article • Mar 20
We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analysis Article • Dec 02
Will ANGLE (LON:AGL) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analysis Article • Aug 11
We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Feb 28
We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Jul 16
ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Shareholder Returns
| CLBX | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -4.1% | -0.9% | 2.4% |
| 1Y | -77.8% | -6.0% | 18.2% |
Return vs Industry: CLBX underperformed the UK Medical Equipment industry which returned -6.7% over the past year.
Return vs Market: CLBX underperformed the UK Market which returned 18.3% over the past year.
Price Volatility
| CLBX volatility | |
|---|---|
| CLBX Average Weekly Movement | 15.6% |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: CLBX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: CLBX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 119 | Peter Collins | cellbxhealth.com |
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology.
CelLBxHealth plc Fundamentals Summary
| CLBX fundamental statistics | |
|---|---|
| Market cap | UK£20.17m |
| Earnings (TTM) | -UK£15.78m |
| Revenue (TTM) | UK£2.62m |
7.7x
P/S Ratio-1.3x
P/E RatioIs CLBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLBX income statement (TTM) | |
|---|---|
| Revenue | UK£2.62m |
| Cost of Revenue | UK£1.80m |
| Gross Profit | UK£823.00k |
| Other Expenses | UK£16.60m |
| Earnings | -UK£15.78m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Jun 22, 2026
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 31.36% |
| Net Profit Margin | -601.37% |
| Debt/Equity Ratio | 0% |
How did CLBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 05:10 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CelLBxHealth plc is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam McCarter | Cavendish |
| Lucy Codrington | Edison Investment Research |
| Lucy Codrington | Jefferies LLC |